Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Nutr.

Sec. Nutritional Immunology

Volume 12 - 2025 | doi: 10.3389/fnut.2025.1650929

This article is part of the Research TopicNutritional Impacts on Human Tumor Development and Immune SystemView all 17 articles

Decoding Iron Deficiency in Cancer: Mechanisms, Immune Modulation, and Therapeutic Potential

Provisionally accepted
  • 1The First Hospital of Jilin University, Changchun, China
  • 2University of the Chinese Academy of Sciences Wenzhou Institute, Wenzhou, China

The final, formatted version of the article will be published soon.

Iron is a vital micronutrient in many biological functions, including DNA metabolism, oxygen transport, and cellular energy generation. In this context, it is intimately linked to cancer biology. However, although many studies have comprehensively investigated and reviewed the effects of excess iron on tumor initiation and progression, the potential interrelations of iron deficiency with tumors have been largely neglected and need to be better defined. Recent studies have highlighted the complex relationship between iron deficiency and tumor biology. Iron deficiency in specific tumor types can promote tumor progression through activation of hypoxic responses, metabolic reprogramming, and suppression of the immune response, as well as inhibit tumor growth by limiting tumor cell proliferation, among other mechanisms. This review aims to systematically explore the dual mechanisms of iron deficiency in tumors, its specific effects in different tumor types, its impact on tumor metabolism, immune responses, and therapy, and its prospects as a potential therapeutic target. Furthermore, the potential of iron metabolism markers in tumor diagnosis and prognosis is discussed. By synthesizing existing evidence, this paper comprehensively explains how iron deficiency affects tumorigenesis and identifies future research and clinical practice directions.

Keywords: iron deficiency, tumor progression, immune response, tumor metabolism, therapeutic targets

Received: 20 Jun 2025; Accepted: 29 Sep 2025.

Copyright: © 2025 Lin, Guan and Yin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Yi Guan, guanyi@jlu.edu.cn
Xunzhe Yin, xzyin@ciac.ac.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.